RNAZ
NASDAQTransCode Therapeutics Inc.
News25/Ratings0
News · 26 weeks42-33%
2026-04-262026-10-18
Mix2190d
- SEC Filings8(38%)
- Other8(38%)
- Insider4(19%)
- Offering1(5%)
Latest news
25 items- PRNatera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal CancerTransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic collaboration in colorectal cancer (CRC). The collaboration will support enrollment for TransCode’s Phase 2a trial evaluating TTX-MC138 in patients with CRC. Patients will be eligible for enrollment if they have completed curative-intent therapy and remain positive for molecular residual disease (MRD), as detecte
- SECTransCode Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
- SECTransCode Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
- PRTransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-UpUpdated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumorsIn the 14 efficacy-evaluable patients:71.4% stable disease rate57.1% of patients had disease control through three months of therapy36.7% maintained disease control through six months of therapyThree efficacy-evaluable patients remain progression-free at one yearExploratory blood RNA-sequencing showed treatment-associated antitumor immune activation and biological features associated with stable disease. The primary endpoint of the study was metNo dose-limiting toxicities were reported across the evaluated dose levelsBOSTON, Sept. 28, 2026 /PRNewswire/ -- TransCode Therape
- PRTransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-OncologyAllowances of Patent Applications in Australia and Japan support differentiated RNA platform for targeted cancer therapy and immune modulationBOSTON, Sept. 22, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced significant advancements in its global intellectual property portfolio, highlighted by (i) the acceptance of an Australian patent application and (ii) the issuance of a Notice of Allowance from the Japan Patent Office (JPO) for key technologies underpinning its RNA-based therapeutic platform.
- INSIDERSEC Form 3 filed by new insider Tattory John A3 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Fitzgerald Thomas A4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
- SECTransCode Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
- PRTransCode Therapeutics Announces Leadership TransitionTom Fitzgerald, Chief Financial Officer, Announces his RetirementJohn Tattory, to become Interim Chief Financial OfficerBOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald. Mr. Fitzgerald has served as the Chief Financial Officer of TransCode Therapeutics since July 2018, during which time he helped lead the company through its initial public offering, the launch of its clinical program for lead product candidate, TTX-MC138, and most recently its acquisition of Polynoma and
- PRTransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone MetastasisPublished study in Cancers highlights therapeutic potential of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidateBOSTON, Aug. 31, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a peer-reviewed article in Cancers titled, "Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based Therapeutics." The study reports that TransCode's lead therapeutic candidate, TTX-MC138, produced significant survival benefits in a preclinical model of breast c
- SECSEC Form 10-Q filed by TransCode Therapeutics Inc.10-Q - Transcode Therapeutics, Inc. (0001829635) (Filer)
- INSIDERLarge owner Defj, Llc converted options into 13,834,441 shares (SEC Form 4)4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
- INSIDERNew insider Defj, Llc claimed ownership of 300,040 shares (SEC Form 3)3 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by TransCode Therapeutics Inc.SCHEDULE 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
- SECTransCode Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
- SECSEC Form SCHEDULE 13G filed by TransCode Therapeutics Inc.SCHEDULE 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by TransCode Therapeutics Inc.SCHEDULE 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by TransCode Therapeutics Inc.SCHEDULE 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
- SECSEC Form 424B3 filed by TransCode Therapeutics Inc.424B3 - Transcode Therapeutics, Inc. (0001829635) (Filer)
- SECSEC Form 424B3 filed by TransCode Therapeutics Inc.424B3 - Transcode Therapeutics, Inc. (0001829635) (Filer)
- SECTransCode Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by TransCode Therapeutics Inc.SCHEDULE 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
- SECSEC Form DEFA14A filed by TransCode Therapeutics Inc.DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
- SECTransCode Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
- SECTransCode Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
RNAZ FAQ
5 questionsWhere does RNAZ stock trade?
TransCode Therapeutics Inc. (RNAZ) is listed on NASDAQ.What sector and industry is RNAZ in?
TransCode Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did TransCode Therapeutics Inc. go public?
TransCode Therapeutics Inc. (RNAZ) completed its IPO in 2021.What companies are similar to RNAZ?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RNAZ side-by-side with any of them on Quantisnow.How can I track RNAZ on Quantisnow?
Quantisnow aggregates TransCode Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RNAZ to receive live email and push alerts on every new disclosure.